carboplatin,plx2853
opna-io
['gyn', 'ct160', 'ovarian', 'carboplatin']
#aacr23 | section 47 | monday
ct160 - phase 1b/2a clinical trial of the oral bet inhibitor plx2853 as monotherapy for arid1a mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer
oladapo yeku, md, phd, facp 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.